Market news
Firefly Neuroscience partners with NeuroSigma to expand access to the FDA-cleared Monarch eTNS non-drug ADHD treatment nationwide.
Gainers Firefly Neuroscience (NASDAQ:AIFF) shares increased by 33.2% to $1.58 during Friday's regular session. The company's market cap stands at $18.6 million. Apimeds Pharmaceuticals (AMEX:APUS) shares moved
Detailed price information for Firefly Neuroscience Inc (AIFF-Q) from The Globe and Mail including charting and trades.
Commercial momentum continues to build, while Firefly harnesses increased electrophysiological data combining EEG and ERG to unlock future valueKENMORE, N.Y., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence ("AI") company advancing precision neuroscience, today announced a close to four-fold (291%) year-over-year increase in Transcranial Magnetic Stimulation (“TMS”) center customer clinical assessments using its
This is the newest page. Registered accounts read further back.